BackAspen Pharmacare Holdings Overview

Aspen Pharmacare Holdings Other Current Assets

Track Aspen Pharmacare Holdings's other current assets ($11B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$10.70B
1032.48% YoYΔ $9.76B vs prior year quarter

Peer average / median

Loading

Aspen Pharmacare Holdings Other Current Assets History

Loading

Aspen Pharmacare Holdings vs. peers: Other Current Assets Comparison

Loading

Aspen Pharmacare Holdings Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Aspen Pharmacare Holdings (APNHY) FAQ

Aspen Pharmacare Holdings posts a other current assets of $11B as of June 2026. That compares with $950M in the prior-year period — up 1032.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Aspen Pharmacare Holdings's other current assets was $950M. The latest reading is $11B — a 1032.5% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Other Current Assets is one piece of Aspen Pharmacare Holdings's financial statement story. At $11B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for APNHY's other current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Aspen Pharmacare Holdings's other metric pages and overview cover the third.

Judging Aspen Pharmacare Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current assets easier to interpret. Start with $11B here, then scan peer and history charts to see if the gap is persistent.